CCM
PFE icon

Carderock Capital Management’s Pfizer PFE Stock Holding History

Carderock Capital Management’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,200
Closed -$77.6K – 110
2025
Q2 		$77.6K Buy
+3,200
New +$74.6K 0.02% 97
2023
Q2 		– Sell
-1,800
Closed -$73.4K – 105
2023
Q1 		$73.4K Buy
+1,800
New +$77.7K 0.03% 83
2014
Q2 		– Sell
-882
Closed -$27K – 178
2014
Q1 		$27K Buy
+882
New +$26.3K 0.01% 167

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Carderock Capital Management's PFE Position: Q3 2025 in Review

Carderock Capital Management sold out of Pfizer (PFE) in Q3 2025, closing a stake of 3,200 shares — an estimated $77.6K sold.

Carderock Capital Management first reported a position in PFE in Q1 2014 and held it in 3 quarters. The position peaked at $77.6K in Q2 2025. 2,812 funds tracked by Wall St. Rank hold PFE as of Q3 2025.

  • Carderock Capital Management reported no remaining Pfizer position as of Q3 2025 after selling out during the quarter.
  • Carderock Capital Management sold 3,200 Pfizer shares in Q3 2025, an estimated $77.6K.
  • Carderock Capital Management first reported a position in Pfizer in Q1 2014 and held it in 3 quarters.
  • Carderock Capital Management's Pfizer position peaked at $77.6K in Q2 2025.
  • 2,812 funds tracked by Wall St. Rank held Pfizer as of Q3 2025.

Based on Carderock Capital Management's 13F filing for Q3 2025, filed 17 Oct 2025.